Compounds > n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide
Page last updated: 2024-09-03

n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide and Allergic Encephalomyelitis

n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide has been researched along with Allergic Encephalomyelitis in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chim, B; Dashnyam, M; Dulcey, AE; Escobar, TM; Ferrer, M; Hu, X; Jadhav, A; Koganti, PP; Lazarevic, V; Marugan, J; Muljo, SA; Selvaraj, V; Singh, A; Southall, N; Spinner, CA; Wilson, KM; Xu, X1

Other Studies

1 other study(ies) available for n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide and Allergic Encephalomyelitis

ArticleYear
Anxiolytic Drug FGIN-1-27 Ameliorates Autoimmunity by Metabolic Reprogramming of Pathogenic Th17 Cells.
    Scientific reports, 2020, 02-28, Volume: 10, Issue:1

    Topics: Animals; Anti-Anxiety Agents; Autoimmunity; Cellular Reprogramming Techniques; Encephalomyelitis, Autoimmune, Experimental; Indoleacetic Acids; Mice; Mice, Transgenic; Receptors, GABA; Th17 Cells

2020